Avula Bharathi, Chittiboyina Amar G, Sagi Satyanarayanaraju, Wang Yan-Hong, Wang Mei, Khan Ikhlas A, Cohen Pieter A
National Center for Natural Products Research, School of Pharmacy, University of Mississippi, University, MS, 38677, USA.
Division of Pharmacognosy, Department of BioMolecular Sciences, School of Pharmacy, The University of Mississippi, University, MS, 38677, USA.
Drug Test Anal. 2016 Mar-Apr;8(3-4):334-43. doi: 10.1002/dta.1853. Epub 2015 Oct 1.
Vinpocetine and picamilon are drugs prescribed in many countries to treat a variety of cerebrovascular disorders. In the United States, vinpocetine and picamilon have never been approved by the US Food and Drug Administration, but they are both available for sale directly to consumers as dietary supplements. We designed our study to determine the accuracy of supplement labels with regard to the presence and quantity of vinpocetine and picamilon. A validated ultra-high performance liquid chromatography-photodiode-array method was developed for the quantification of vinpocetine and picamilon. The separation was achieved using a reversed phase (C-18) column, photodiode array detection, and water/acetonitrile as the mobile phase. Vinpocetine and picamilon were detected at concentrations as low as 10 and 50 ng/mL, respectively. The presence of vinpocetine and picamilon was confirmed using reference standards. Twenty-three supplements labelled as containing vinpocetine were available for sale at two large supplement retail chains; 17 contained vinpocetine with quantities ranging from 0.3 to 32 mg per recommended daily serving. No vinpocetine was detected in six of the sampled supplements. The supplement label implied that vinpocetine was a constituent of lesser periwinkle in three of the supplements. Of the 31 picamilon supplements available for sale from a variety of retailers: 30 contained picamilon in quantities ranging from 2.7 to 721.5 mg per recommended daily serving. We found that consumers cannot obtain accurate information from supplement labels regarding the presence or quantity of vinpocetine and picamilon. Copyright © 2015 John Wiley & Sons, Ltd.
长春西汀和匹卡米隆是许多国家用于治疗各种脑血管疾病的药物。在美国，长春西汀和匹卡米隆从未获得美国食品药品监督管理局的批准，但它们都作为膳食补充剂直接向消费者出售。我们设计这项研究以确定补充剂标签中关于长春西汀和匹卡米隆的存在情况及含量的准确性。开发了一种经过验证的超高效液相色谱 - 光电二极管阵列方法用于定量长春西汀和匹卡米隆。使用反相（C - 18）柱、光电二极管阵列检测以及水/乙腈作为流动相实现分离。长春西汀和匹卡米隆分别在低至10和50 ng/mL的浓度下被检测到。使用参考标准品确认了长春西汀和匹卡米隆的存在。在两家大型补充剂零售连锁店有23种标注含有长春西汀的补充剂在售；17种含有长春西汀，每份推荐日剂量的含量范围为0.3至32毫克。在六个抽样补充剂中未检测到长春西汀。其中三种补充剂的标签暗示长春西汀是小蔓长春花的一种成分。在从各类零售商处在售的31种匹卡米隆补充剂中：30种含有匹卡米隆，每份推荐日剂量的含量范围为2.7至721.5毫克。我们发现消费者无法从补充剂标签中获得关于长春西汀和匹卡米隆的存在情况或含量的准确信息。版权所有© 2015约翰威立父子有限公司。
